Udenafil CAS 268203-93-6

Udenafil is the fourth in a class of drugs targeting the inhibition of the enzyme phosphodiesterase 5 (PDE5) for the treatment of erectile dysfunction. Inhibition of PDE5 results in the increase in endogenous cyclic guanosine monophosphate (cGMP) concentrations in the penile corpus cavernosum. cGMP induces smooth muscle cell relaxation and subsequent increased blood flow leading to a sustainable erection. Udenafil is a potent antagonist of human PDE5 with an IC₅₀ of 8.25nM and a comparable selectivity profile as sildenafil for the other PDEs. Unlike tadalafil, it does not inhibit PDE11, which has been implicated in myalgia and testicular toxicity. Furthermore, udenafil produced up to a 91% vaginal penetration success rate and up to a 67% intercourse completion rate compared to a 29% completion rate by placebo. Overall patient satisfaction, measured by a standard global assessment question, was 86% compared to only 26% in the placebo group. The most frequently recorded adverse events were mild-to-moderate facial flushing and headache.

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5). In vivo, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension. It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury. Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.

Għandna ħafna fabbriki ta 'kwalità għolja b'kooperazzjoni profonda, li jistgħu jagħtuk prodotti ta' kwalità għolja u prezzijiet kompetittivi. U nistgħu wkoll nagħtu skontijiet għal xiri bl-ingrossa. U aħna nikkooperaw ma 'ħafna kumpaniji professjonali tal-ġarr tal-merkanzija, nistgħu nwasslu prodotti b'mod sikur u bla xkiel f'idejk. Il-ħin tal-kunsinna huwa ta 'madwar 3-20 jum wara l-konferma tal-ħlas.

Product Name:	Udenafil
Synonyms:	5-[2-propyloxy-5-(2-(1-Methylpyrrolidin-2-yl)ethylaMinosulphonyl)phenyl]-1-Methyl-3-propyl-6,7-dihydro-1H-pyrazolo(4,3-d)pyriMidin-7-one;5-[2-propyloxy-5-[2-(1-Methyl-2-pyrrolidinyl)ethylaMinosulfonyl]phenyl]-1-Methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyriMidine-7-one;Zydena;Udenafil(DA 8159,Zydena);BenzenesulfonaMide,3-(6,7-dihydro-1-Methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyriMidin-5-yl)-N-[2-(1-Methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;Udenafil, DA 8159;CS-1353;Udenafil, >=98%
CAS:	268203-93-6
MF:	C25H36N6O4S
MW:	516.66
EINECS:	251-228-4
Product Categories:	Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:	268203-93-6.mol

1. Inti fabbrika jew kumpanija kummerċjali?
Aħna kumpanija li tintegra l-industrija u l-kummerċ, li nipprovdu servizz one-stop. OEM jista 'jiġi aċċettat.

2. Inti tipprovdi kampjuni? Huwa b'xejn jew żejjed?
Kampjuni b'xejn. It-tariffa tal-merkanzija tal-kampjun trid titħallas min-naħa tiegħek.

3. Għandek xi ċertifikati relatati mal-kontroll tal-kwalità?
Ċertifikazzjoni ISO 9001:2008 biex tiġi żgurata l-kwalità.

4. X'għandi nipprovdi biex tikseb kwotazzjoni?
PLS għarrafna bit-tip ta 'prodott li għandek bżonn, kwantità tal-ordni, indirizz u rekwiżiti speċifiċi. Il-kwotazzjoni ssir għar-referenza tiegħek fil-ħin.

5. X'tip ta 'metodu ta' ħlas tippreferi? X'tip ta' termini huma aċċettati?
Termini ta ' Kunsinna Aċċettati: FOB, CFR, CIF, EXW;
Munita ta 'Ħlas Aċċettata: USD;
Tip ta' Ħlas Aċċettat: T/T,Western Union; Paypal, Assigurazzjoni tal-Kummerċ.
Lingwa Mitkellma: Ingliż.